Gene Therapies

Gene Therapies
On this page

In the centuries-long journey of medical science, one of the greatest peaks reached by humanity has undoubtedly been solving the genetic puzzle. Hereditary eye diseases, which until recently were defined as "hopeless," "progressive," and "resulting in certain blindness," are now transforming into treatable medical conditions thanks to Gene Therapies—the cellular and molecular revolution of the 21st century. As Ophthalmology Specialist Ayşe Öner and her leading clinical team, who command the international literature on genetic retinal diseases, we blend these high-tech treatments that turn science fiction into reality with Turkey's superior healthcare infrastructure. Do not submit to darkness as a fate written in your genes; prepare to be reborn through the light of science.

What is Gene Therapy? Getting to the Root of the Disease

In the nucleus of every cell in the human body lies a manual that determines how that cell works, which proteins it will produce, and how it will survive: the DNA (genetic code). The light-sensitive cells in the retina, which initiate the process of vision, also operate according to these genetic instructions. However, in some cases, a "typo" (mutation) occurs in the genes inherited from parents. Due to this faulty coding, vital proteins required for the retina to function healthily cannot be produced. Consequently, cells degenerate, lose function, and progressive, severe vision loss emerges during childhood, youth, or middle age.

Gene therapy is a revolutionary medical approach that aims to solve the problem not through symptoms (such as merely lowering eye pressure), but directly at the source—the DNA level. The fundamental logic is to replace the faulty or non-functioning gene in the patient's cells with a healthy, normally functioning genetic copy (DNA) produced in a laboratory.

How is Gene Therapy Applied to the Eye? (Viral Vector Technology)

It is impossible for a healthy gene to enter the nucleus of microscopic nerve cells inside the eye on its own. To carry this new and healthy genetic copy into the cell, specialized carriers called "vectors" are needed. The medical world uses viruses—nature's masters at transferring genetic material into human cells—for this transport process.

These are not disease-causing viruses. In a laboratory, Adeno-Associated Viruses (AAV) are used, from which harmful genetic material has been removed, leaving only a "cargo vehicle."

The Application Process:

  1. The healthy gene copy is loaded into these harmless viruses.
  2. The procedure is performed in fully equipped, JCI-accredited smart operating rooms using microsurgical (Vitrectomy) methods.
  3. Using specialized cannulas thinner than a strand of hair, the surgeon performs a precise injection under the retina (subretinal space), delivering millions of "cargo viruses" directly to the target cells.
  4. The viruses transfer the healthy genes to the patient's retinal cells. The cells begin to read this new manual, produce the missing proteins, and the progression of the disease halts immediately, often resulting in striking improvements in vision.

Which Eye Diseases are Treated with Gene Therapy?

The spectrum of gene therapies in ophthalmology is expanding rapidly. Today, in addition to treatments approved by the FDA and EMA, there are dozens of promising Phase-2 and Phase-3 studies:

1. RPE65 Gene Mutation (Luxturna)

This is the greatest success story in modern medicine. It is the treatment for mutations in the RPE65 gene, which causes Leber Congenital Amaurosis (LCA) and some forms of early-onset Retinitis Pigmentosa. With Luxturna, the first approved gene therapy in the world, patients can step from darkness into light very quickly, miraculously increasing their night vision and independent mobility.

2. Other Hereditary Retinal Diseases (In Clinical Trial Stages):

  • Stargardt Disease (ABCA4 Gene): Nano-carriers and gene-editing technologies are being tested for this large gene.
  • Choroideremia (CHM Gene): AAV-vectored gene therapy for this disease, which causes progressive visual field loss and night blindness, is in Phase-3.
  • X-Linked Retinitis Pigmentosa (RPGR Gene): Promising trials continue for this genetic type that progresses severely in males.
  • Achromatopsia: Therapies for the CNGA3 and CNGB3 genes aim to correct extreme light sensitivity and visual acuity.

Future Technology: CRISPR-Cas9 (Gene Editing)

While classic gene therapy adds a "new gene" to the cell, CRISPR-Cas9 (Gene Scissors) technology acts differently. Instead of sending a new gene, it uses microscopic molecular scissors to cut out the "faulty letter" in the patient's own DNA and paste the correct one. CRISPR treatments applied directly to the human eye for LCA Type 10 (CEP290 gene) herald a new era in ophthalmology.

The Vital Importance of Genetic Mapping

To discuss gene therapy, simply knowing the name of the disease (e.g., Night Blindness) is not enough. The "specific gene" causing the disease must be identified in a laboratory. Our clinic provides a comprehensive process:

  • Next-Generation Sequencing (NGS): DNA from blood or saliva is screened for hundreds of retinal genes simultaneously.
  • ERG and OCT: High-tech devices map the viability of retinal cells. We measure with micron-level precision whether enough "living cells" remain to accept the gene therapy.

Frequently asked questions

Can eye gene therapy (Luxturna, etc.) be applied to every Retinitis Pigmentosa patient?

Unfortunately, no. Gene therapies are specific to the "individual and the mutation." There are more than 100 different genes that cause Retinitis Pigmentosa. Currently approved gene therapies (such as Luxturna) are only applicable to patients carrying the "RPE65 or other specific gene mutations." The second golden rule for application is that enough "viable (not completely dead) cells" must remain in your eye to receive the medication.

I have my genetic test result. Is this result alone sufficient for my suitability for treatment?

A genetic test (blood test) on paper is not enough. Even if your genetics match, we must prove that the cells in your retina are functionally alive. For this, international boards strictly require your ERG (Electrophysiological Mapping) and FAF (Metabolic Map) results. An anatomically thin or dead cell cannot accept gene therapy.

This content is for information only; please consult your physician for diagnosis and treatment.

Related pages

Stem Cell Therapy

Stem cells are the fundamental building blocks—the "master" cells—of the human body. They form the origin of all other specialized cells (such as heart muscle, brain…

Exosome Therapy

Exosomes are, in the simplest terms, nano-sized (one-millionth of a millimeter) "cargo packages" or "messenger vesicles" that cells use to communicate, "talk," and help…

PRP and Growth Hormone Injections

PRP (Platelet-Rich Plasma) is a natural, safe, and highly effective cellular regeneration treatment obtained entirely using the patient's own blood. Our blood contains…

Optogenetic Therapies

In hereditary retinal diseases (such as advanced-stage Retinitis Pigmentosa), the primary light-sensing cells, the photoreceptors (rods and cones), completely die over…

Enquiry Form

For information and consultation requests, fill in the form or reach us by phone or WhatsApp.